Israel Englander’s Lineage Cell Therapeutics LCTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.95M | Sell |
3,018,567
-2,542,807
| -46% | -$3.51M | ﹤0.01% | 3227 |
|
|
2026
Q1 | $8.79M | Buy |
5,561,374
+3,450,955
| +164% | +$5.82M | ﹤0.01% | 2297 |
|
|
2025
Q4 | $3.52M | Sell |
2,110,419
-569,584
| -21% | -$986K | ﹤0.01% | 3397 |
|
|
2025
Q3 | $4.53M | Buy |
2,680,003
+79,426
| +3% | +$94K | ﹤0.01% | 3250 |
|
|
2025
Q2 | $2.36M | Buy |
+2,600,577
| New | +$1.54M | ﹤0.01% | 3733 |
|
|
2024
Q3 | – | Sell |
-168,978
| Closed | -$169K | – | 6306 |
|
|
2024
Q2 | $169K | Buy |
168,978
+127,280
| +305% | +$141K | ﹤0.01% | 5195 |
|
|
2024
Q1 | $61.7K | Sell |
41,698
-16,300
| -28% | -$18.5K | ﹤0.01% | 5659 |
|
|
2023
Q4 | $63.2K | Buy |
+57,998
| New | +$63.5K | ﹤0.01% | 5428 |
|
|
2023
Q2 | – | Sell |
-1,402,123
| Closed | -$2.1M | – | 6434 |
|
|
2023
Q1 | $2.1M | Buy |
1,402,123
+1,003,084
| +251% | +$1.4M | ﹤0.01% | 3396 |
|
|
2022
Q4 | $467K | Sell |
399,039
-107,274
| -21% | -$135K | ﹤0.01% | 4794 |
|
|
2022
Q3 | $572K | Sell |
506,313
-514,133
| -50% | -$755K | ﹤0.01% | 4845 |
|
|
2022
Q2 | $1.61M | Buy |
1,020,446
+841,953
| +472% | +$1.11M | ﹤0.01% | 3921 |
|
|
2022
Q1 | $275K | Sell |
178,493
-154,727
| -46% | -$240K | ﹤0.01% | 5617 |
|
|
2021
Q4 | $816K | Buy |
333,220
+313,795
| +1,615% | +$734K | ﹤0.01% | 4605 |
|
|
2021
Q3 | $49K | Buy |
+19,425
| New | +$49.8K | ﹤0.01% | 6576 |
|
|
2021
Q2 | – | Sell |
-1,425,776
| Closed | -$3.35M | – | 6828 |
|
|
2021
Q1 | $3.35M | Buy |
1,425,776
+1,071,023
| +302% | +$2.57M | ﹤0.01% | 3019 |
|
|
2020
Q4 | $624K | Sell |
354,753
-2,775
| -0.8% | -$3.88K | ﹤0.01% | 4037 |
|
|
2020
Q3 | $335 | Buy |
357,528
+343,328
| +2,418% | +$303K | ﹤0.01% | 3781 |
|
|
2020
Q2 | $12K | Buy |
+14,200
| New | +$12.5K | ﹤0.01% | 4104 |
|
|
2019
Q3 | – | Sell |
-54,953
| Closed | -$60K | – | 4379 |
|
|
2019
Q2 | $60K | Buy |
+54,953
| New | +$63.3K | ﹤0.01% | 3943 |
|
|
2019
Q1 | – | Sell |
-18,291
| Closed | -$17K | – | 4164 |
|
|
2018
Q4 | $17K | Sell |
18,291
-7,649
| -29% | -$11.7K | ﹤0.01% | 3674 |
|
|
2018
Q3 | $53K | Buy |
+25,940
| New | +$54.5K | ﹤0.01% | 3804 |
|
|
2018
Q2 | – | Sell |
-129,556
| Closed | -$305K | – | 3996 |
|
|
2018
Q1 | $305K | Sell |
129,556
-42,718
| -25% | -$100K | ﹤0.01% | 3209 |
|
|
2017
Q4 | $324K | Buy |
172,274
+155,683
| +938% | +$340K | ﹤0.01% | 3311 |
|
|
2017
Q3 | $41K | Sell |
16,591
-61,705
| -79% | -$153K | ﹤0.01% | 3423 |
|
|
2017
Q2 | $216K | Sell |
78,296
-129,555
| -62% | -$362K | ﹤0.01% | 3168 |
|
|
2017
Q1 | $627K | Buy |
+207,851
| New | +$590K | ﹤0.01% | 2681 |
|
|
2015
Q3 | – | Sell |
-78,174
| Closed | -$229K | – | 3607 |
|
|
2015
Q2 | $229K | Buy |
+78,174
| New | +$303K | ﹤0.01% | 3000 |
|
|
2014
Q3 | – | Sell |
-21,559
| Closed | -$53K | – | 3860 |
|
|
2014
Q2 | $53K | Buy |
+21,559
| New | +$48.7K | ﹤0.01% | 3303 |
|
Other funds holding LCTX
BC
DC
RA
Israel Englander's LCTX Position: Q2 2026 in Review
Israel Englander reduced its Lineage Cell Therapeutics (LCTX) stake by 46% in Q2 2026, selling an estimated $3.51M and leaving 3,018,567 shares worth $3.95M. The position accounts for ﹤0.01% of the portfolio, ranked #3227.
Israel Englander first reported a position in LCTX in Q2 2014 and has held it in 29 quarters since. The position peaked at $8.79M in Q1 2026. 131 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.
- Israel Englander held 3,018,567 shares of Lineage Cell Therapeutics worth $3.95M as of Q2 2026.
- Israel Englander sold 2,542,807 Lineage Cell Therapeutics shares in Q2 2026, an estimated $3.51M.
- Lineage Cell Therapeutics made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #3227 holding.
- Israel Englander first reported a position in Lineage Cell Therapeutics in Q2 2014 and has held it in 29 quarters since.
- Israel Englander's Lineage Cell Therapeutics position peaked at $8.79M in Q1 2026.
- 131 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.
Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.